These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 24398307

  • 1. [The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].
    Wu Y, Guo L, Liu J, Liu R, Liu M, Chen J.
    Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):1-7. PubMed ID: 24398307
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH, Luo N, Zhong MZ, Xiao ZQ, Wang JX, Yao XY, Peng Y, Cao J.
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [Abstract] [Full Text] [Related]

  • 3. [The effect and mechanism of vinorelbine on cisplatin resistance of human lung cancer cell line A549/DDP].
    Qi C, Gao S, Li H, Gao W.
    Zhongguo Fei Ai Za Zhi; 2014 Feb; 17(2):148-54. PubMed ID: 24581167
    [Abstract] [Full Text] [Related]

  • 4. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
    Guo J, Jin D, Wu Y, Yang L, Du J, Gong K, Chen W, Dai J, Miao S, Xi S.
    EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
    Yu G, Zhong N, Chen G, Huang B, Wu S.
    Tumour Biol; 2014 Oct; 35(10):10341-9. PubMed ID: 25038915
    [Abstract] [Full Text] [Related]

  • 9. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B, Wang R, Liu H.
    Biomed Res Int; 2021 Oct; 2021():6622342. PubMed ID: 34055989
    [Abstract] [Full Text] [Related]

  • 10. LDR reverses DDP resistance in ovarian cancer cells by affecting ERCC-1, Bcl-2, Survivin and Caspase-3 expressions.
    Ju X, Yu H, Liang D, Jiang T, Liu Y, Chen L, Dong Q, Liu X.
    Biomed Pharmacother; 2018 Jun; 102():549-554. PubMed ID: 29597088
    [Abstract] [Full Text] [Related]

  • 11. [Effect of Src tyrosine kinase inhibition on the drug-resistance as well as MDR1 and LRP expression of the human cis-platinum-resistant lung cancer cell line A549/DDP].
    Lv J, Tian Y.
    Zhongguo Fei Ai Za Zhi; 2012 Sep; 15(9):501-6. PubMed ID: 22989452
    [Abstract] [Full Text] [Related]

  • 12. LncRNA NORAD targets miR-410-3p to regulate drug resistance sensitivity of osteosarcoma.
    Xie X, Liu W, Duan Z, Li X, Zhang L, Yang G.
    Cell Mol Biol (Noisy-le-grand); 2020 Jun 05; 66(3):143-148. PubMed ID: 32538761
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM, Ge F, Chen XJ, Tang C, Ma J.
    Eur Rev Med Pharmacol Sci; 2019 Jun 05; 23(12):5242-5250. PubMed ID: 31298375
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.
    Chu D, Li P, Li Y, Shi J, Huang S, Jiao P.
    Thorac Cancer; 2021 Nov 05; 12(21):2894-2906. PubMed ID: 34523261
    [Abstract] [Full Text] [Related]

  • 18. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A, Li H, Li R, Lu L, Wu X.
    Oncol Rep; 2018 Oct 05; 40(4):2353-2362. PubMed ID: 30066933
    [Abstract] [Full Text] [Related]

  • 19. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
    Zhu X, Zhang K, Wang Q, Chen S, Gou Y, Cui Y, Li Q.
    Zhonghua Zhong Liu Za Zhi; 2015 Jun 05; 37(6):404-11. PubMed ID: 26463141
    [Abstract] [Full Text] [Related]

  • 20. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.
    Mei J, Liu G, Li R, Xiao P, Yang D, Bai H, Hao Y.
    Biosci Rep; 2021 Dec 22; 41(12):. PubMed ID: 34821362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.